Sanofi, Cel­lec­tis team up to pair Lem­tra­da with al­lo­gene­ic CAR-Ts; Bris­tol My­ers joins Evotec's dri­ve to ad­vance UK sci­ence

Sanofi is part­ner­ing up with Cel­lec­tis on their al­lo­gene­ic CAR-Ts.

Cel­lec­tis struck a deal to use the French phar­ma’s drug alem­tuzum­ab (Lem­tra­da, an MS agent) …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER